Septerna is a clinical-stage biotech firm that develops oral small molecule treatments targeting G protein-coupled receptors for conditions in endocrinology, immunology, inflammation, and metabolic disease. The company's pipeline includes candidates for hypoparathyroidism, chronic spontaneous urticaria, and graves' disease, with additional programs in neurology, women's health, cardiovascular, and respiratory areas. Septerna has a global partnership with Novo Nordisk to research and develop oral therapies for metabolic diseases.

entry readiness 22 · NOT READY · exit proximity 15

Value area 22.78–37.51 · 18% of 120d volume overhead · clean runway